

23 October 2025

## **Diagnosis and Treatment of Spinal Muscular Atrophy**

**Question 1. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust?**

There are 11 patients currently in children's with a diagnosis of Spinal Muscular Atrophy.

**Question 2. How many patients have been treated in the last 4 months (May to August 2025) with the following products:**

- Evrysdi (Risdiplam) - <10
- Spinraza (Nusinersen) - <10
- Zolgensma (Onasemnogene) - 0
- Evrysdi (Risdiplam) - <10
- Spinraza (Nusinersen) - 0
- Zolgensma (Onasemnogene) - 0

**\*new patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam) or Zolgensma (Onasemnogene) in the previous 4-month period (January to April 2025).**

**Question 3. Of the total patients treated in the last 4 months (May to August 2025) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (January to April 2025).**

0

**Question 4. Of the total patients treated in the last 4 months (May to August 2025) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (January to April 2025).**

0

**Question 5. Of the total patients treated in the last 4 months (May to August 2025) with Spinraza (Nusinersen) please provide the number of patients that were treated with Evrysdi (Risdiplam) in the previous 4 months (January to April 2025).**

0



**23 October 2025**

(Response unbolded) xxxxxxxxx